Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections

Journal of Clinical Virology

Volumn 27, Issue 1, 2003, Pages 59-68

  Andrieu, T ^a   Thibault, V ^a   Malet, I ^a   Laporte, J ^a   Bauvois, B ^b   Agut, H ^a   Cahour, A ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT CURIE   (France)

Author keywords

Cholestasis; DPPIV CD26; Fibrosis; HCV; Pathophysiology; Viral infection

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DIPEPTIDYL PEPTIDASE IV; GAMMA GLUTAMYLTRANSFERASE;

ARTICLE; COLORIMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; EPSTEIN BARR VIRUS; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLAMMATION; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; VIRUS INFECTION;

ADULT; ANTIGENS, CD26; CHOLESTASIS; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; VIRUS DISEASES;

EID: 0037407316     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(02)00128-2     Document Type: Article

References (41)

1. Antczak C., De Meester I., Bauvois B. Ectopeptidases in pathophysiology. Bioessays. 23:2001a;251-260.
2. Antczak C., De Meester I., Bauvois B. Transmembrane proteases as disease markers and targets for therapy. J. Biol. Regul. Homeost. Agents. 15:2001b;130-139.
3. Bauvois B. Murine thymocytes possess specific cell surface-associated exoaminopeptidase activities: preferential expression by immature CD4- CD8- subpopulation. Eur. J. Immunol. 20:1990;459-468.
4. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 24:1996;289-293.
5. Bertoletti A., Maini M.K. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr. Opin. Microbiol. 3:2000;387-392.
6. Cerny A., Chisari F.V. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology. 30:1999;595-601.
7. Chikuma T., Hama T., Nagatsu T., Kumegawa M., Kato T. Purification and properties of dipeptidyl peptidase IV from human urine. Biol. Chem. Hoppe Seyler. 371:1990;325-330.
8. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., et al. Analysis of a successful immune response against hepatitis C virus. Immunity. 10:1999;439-449.
9. De Meester I., Korom S., Van Damme J., Scharpe S. CD26, let it cut or cut it down. Immunol. Today. 20:1999;367-375.
10. Durinx C., Neels H., Van der Auwera J.C., Naelaerts K., Scharpe S., De Meester I. Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin. Chem. Lab. Med. 39:2001;155-159.
11. Firneisz G., Lakatos P.L., Szalay F. Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C. Scand. J. Gastroenterol. 36:2001;877-880.
12. Fleischer B. CD26: a surface protease involved in T-cell activation. Immunol. Today. 15:1994;180-184.
13. Friedman S.L. Molecular mechanisms of hepatic fibrosis and principles of therapy. J. Gastroenterol. 32:1997;424-430.
14. Gaetaniello L., Fiore M., de Filippo S., Pozzi N., Tamasi S., Pignata C. Occupancy of dipeptidyl peptidase IV activates an associated tyrosine kinase and triggers an apoptotic signal in human hepatocarcinoma cells. Hepatology. 27:1998;934-942.
15. Harada T., Kim D.W., Sagawa K., Suzuki T., Takahashi K., Saito I., et al. Characterization of an established human hepatoma cell line constitutively expressing non-structural proteins of hepatitis C virus by transfection of viral cDNA. J. Gen. Virol. 76:1995;1215-1221.
16. He X.S., Rehermann B., Lopez-Labrador F.X., Boisvert J., Cheung R., Mumm J., et al. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc. Natl. Acad. Sci. USA. 96:1999;5692-5697.
17. Hegen M., Niedobitek G., Klein C.E., Stein H., Fleischer B. The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J. Immunol. 144:1990;2908-2914.
18. Heike M., Mobius U., Knuth A., Meuer S., Meyer zum Buschenfelde K.H. Tissue distribution of the T cell activation antigen Ta1. Serological, immunohistochemical and biochemical investigations. Clin. Exp. Immunol. 74:1988;431-434.
19. Iwata S., Morimoto C. CD26/dipeptidyl peptidase IV in context. The different roles of a multifunctional ectoenzyme in malignant transformation. J. Exp. Med. 190:1999;301-306.
20. Kameoka J., Tanaka T., Nojima Y., Schlossman S.F., Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science. 261:1993;466-469.
21. Kasahara Y., Leroux-Roels G., Nakamura R., Chisari F. Glycylprolyl-diaminopeptidase in human leukocytes: selective occurrence in T lymphocytes and influence on the total serum enzyme activity. Clin. Chim. Acta. 139:1984;295-302.
22. Kullak-Ublick G.A., Beuers U., Paumgartner G. Hepatobiliary transport. J. Hepatol. 32:2000;3-18.
23. Lakatos P.L., Firneisz G., Borcsiczky D., Zalatnai A., Selmeci L., Szalay F. Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis. Eur. J. Clin. Invest. 30:2000;793-797.
24. Lakatos P.L., Firneisz G., Rakoczy G., Selmeci L., Szalay F. Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in patients with primary biliary cirrhosis. letter J. Hepatol. 30:1999;740.
25. Levy M.T., McCaughan G.W., Abbott C.A., Park J.E., Cunningham A.M., Muller E., et al. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology. 29:1999;1768-1778.
26. Maes M., Scharpe S., De Meester I., Goossens P., Wauters A., Neels H., et al. Components of biological variation in prolyl endopeptidase and dipeptidyl-peptidase IV activity in plasma of healthy subjects. Clin. Chem. 40:1994;1686-1691.
27. Matsumoto Y., Bishop G.A., McCaughan G.W. Altered zonal expression of the CD26 antigen (dipeptidyl peptidase IV) in human cirrhotic liver. Hepatology. 15:1992;1048-1053.
28. McCaughan G.W., Gorrell M.D., Bishop G.A., Abbott C.A., Shackel N.A., McGuinness P.H., et al. Molecular pathogenesis of liver disease: an approach to hepatic inflammation, cirrhosis and liver transplant tolerance. Immunol. Rev. 174:2000;172-191.
29. McCaughan G.W., Wickson J.E., Creswick P.F., Gorrell M.D. Identification of the bile canalicular cell surface molecule GP110 as the ectopeptidase dipeptidyl peptidase IV: an analysis by tissue distribution, purification and N-terminal amino acid sequence. Hepatology. 11:1990;534-544.
30. Perner F., Gyuris T., Rakoczy G., Sarvary E., Gorog D., Szalay F., et al. Dipeptidyl peptidase activity of CD26 in serum and urine as a marker of cholestasis: experimental and clinical evidence. J. Lab. Clin. Med. 134:1999;56-67.
31. Piazza G.A., Callanan H.M., Mowery J., Hixson D.C. Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix. Biochem. J. 262:1989;327-334.
32. Poupon R., Chazouilleres O., Poupon R.E. Chronic cholestatic diseases. J. Hepatol. 32:2000;129-140.
33. Poynard T., Ratziu V., Benmanov Y., Martino V.D., Bedossa P., Opolon P. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin. Liver Dis. 20:2000;47-55.
34. Rakoczi G., Takacs L., Jakabfi P., Kunos I., Selmeci L., Gyuris T., et al. Increased urinary dipeptidyl peptidase IV activity in extrahepatic biliary atresia. Lancet. 345:1995;864-865.
35. Rehermann B. Interaction between the hepatitis C virus and the immune system. Semin. Liver Dis. 20:2000;127-141.
36. Rehermann B., Chisari F.V. Cell mediated immune response to the hepatitis C virus. Curr. Top. Microbiol. Immunol. 242:2000;299-325.
37. Stecca B.A., Nardo B., Chieco P., Mazziotti A., Bolondi L., Cavallari A. Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma. J. Hepatol. 27:1997;337-345.
38. Tanaka T., Kameoka J., Yaron A., Schlossman S.F., Morimoto C. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc. Natl. Acad. Sci. USA. 90:1993;4586-4590.
39. Torimoto Y., Dang N.H., Tanaka T., Prado C., Schlossman S.F., Morimoto C. Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies. Mol. Immunol. 29:1992;183-192.
40. Valiante N.M., D'Andrea A., Crotta S., Lechner F., Klenerman P., Nuti S., et al. Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C. Immunol. Rev. 174:2000;77-89.
41. Vanhoof G., De Meester I., van Sande M., Scharpe S., Yaron A. Distribution of proline-specific aminopeptidases in human tissues and body fluids. Eur. J. Clin. Chem. Clin. Biochem. 30:1992;333-338.